| 本文已被：浏览 55次 下载 30次 |
码上扫一扫！ |
|
|
| 基于UPLC-Q-TOF-MS网络药理学及实验验证探讨引火汤治疗肺腺癌的药效物质与作用机制 |
|
史恩泽1,2, 李泉旺2, 林事成1,2, 王玥慧1,2, 杜若芳1,2, 刘殿娜3
|
|
1.北京中医药大学, 北京 100029;2.北京中医药大学东方医院肿瘤科, 北京 100078;3.北京中医药大学东方医院科研处, 北京 100078
|
|
| 摘要: |
| [目的] 探索引火汤治疗肺腺癌的药效物质基础及作用机制。[方法] 基于超高效液相色谱-四极杆-飞行时间串联质谱（UPLC-Q-TOF-MS）技术分析引火汤入血成分，结合PubChem等数据库获取成分作用靶点；用GeneCards、OMIM等数据库获取肺腺癌靶点信息；构建引火汤治疗肺腺癌潜在靶点的蛋白质互作（PPI）网络，进行基因本体论（GO）和京都基因与基因组百科全书（KEGG）富集分析。制备引火汤含药血清干预A549、H1299肺腺癌细胞株，CCK8法确定最佳干预浓度及干预时间，采用大鼠肉瘤（RAS）激活剂ML-098进行挽救实验。划痕实验观察细胞迁移能力；免疫印迹杂交法测定丝裂原活化蛋白激酶病毒癌基因（MAPK）/细胞外信号调节激酶（ERK）通路关键分子蛋白表达。[结果] 检测出21个引火汤入血成分，获574个药物潜在靶点、1 341个肺腺癌治疗潜在靶点和176个交集靶点。KEGG分析显示引火汤通过影响癌症、RAS、MAPK等信号通路发挥抗肺腺癌作用。体外实验表明，引火汤可抑制A549与H1299细胞迁移（P<0.05）。与空白对照组相比，引火汤组MAPK/ERK通路关键蛋白表达降低（P<0.05），引火汤+ML-098组与空白对照组无差异（P>0.05），引火汤抑制作用可被ML-098逆转。[结论] 引火汤能有效抑制肺腺癌细胞迁移能力，作用机制可能与MAPK/ERK信号通路相关。 |
| 关键词: 引火汤 肺腺癌 入血分析 细胞实验 |
| DOI：10.11656/j.issn.1672-1519.2026.07.09 |
| 分类号:R285.5 |
| 基金项目:国家自然科学基金项目（82405515）；中央高水平中医医院临床科研业务费资助（DFRCZY-2024ARC-003）；岐黄英才·名医培育计划（Y2023A08）。 |
|
| Exploration on the effective substances and mechanism of action of Yinhuo Tang in the treatment of lung adenocarcinoma based on UPLC-Q-TOF-MS，network pharmacology and experimental verification |
|
SHI Enze1,2, LI Quanwang2, LIN Shicheng1,2, WANG Yuehui1,2, DU Ruofang1,2, LIU Dianna3
|
|
1.Beijing University of Chinese Medicine, Beijing 100029, China;2.Department of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China;3.Research Office, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
|
| Abstract: |
| [Objective] To explore the pharmacodynamic material basis and mechanism of Yinhuo Tang in treating lung adenocarcinoma. [Methods] The blood-entry components of Yinhuo Tang were analyzed by UPLC-Q-TOF-MS technology，and the component targets were obtained by combining PubChem and other databases. The targets of lung adenocarcinoma were obtained by using GeneCards， OMIM and other databases. The protein-protein interaction（PPI）network of potential targets for Yinhuo Tang in treating lung adenocarcinoma was constructed，and GO and KEGG enrichment analysis were carried out. Yinhuo Tang-containing serum was prepared to intervene in A549 and H1299 lung adenocarcinoma cell lines. CCK8 method was used to determine the optimal intervention concentration and time，and RAS activator ML-098 was used for rescue experiments. The cell migration ability was observed by scratch assay，and the protein expression of key molecules in MAPK/ERK pathway was detected by Western blot. [Results] The 21 blood-entry components of Yinhuo Tang were detected，and 574 potential drug targets，1 341 potential targets for lung adenocarcinoma treatment and 176 intersection targets were obtained. KEGG analysis showed that Yinhuo Tang might exert anti-lung cancer effects by affecting cancer，Ras，MAPK and other signaling pathways. In vitro experiments showed that Yinhuo Tang could inhibit the migration of A549 and H1299 lung cancer cells（P<0.05）. Compared with the blank control group，the expression of key proteins in MAPK/ERK pathway in the Yinhuo Tang group was decreased（P<0.05）. There was no significant difference between the Yinhuo Tang + ML-098 group and the blank control group（P>0.05），indicating that the inhibitory effect of Yinhuo Tang could be reversed by ML-098. [Conclusion] Yinhuo Tang can effectively inhibit the migration ability of lung adenocarcinoma cells，and its mechanism may be related to the MAPK/ERK signaling pathway. |
| Key words: YinhuoTang lung adenocarcinoma blood analysis cell experiment |
